Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology, and management

American Journal of Hematology

Volumn 83, Issue 1, 2008, Pages 63-70

  Aliyu, Zakari Y ^a,b,c,d   Kato, Gregory J ^a,d   Taylor IV, James ^a   Babadoko, Aliyu ^c   Mamman, Aisha I ^c   Gordeuk, Victor R ^b   Gladwin, Mark T ^a,d  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c AHMADU BELLO UNIVERSITY   (Nigeria)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CELL ADHESION MOLECULE; ENDOTHELIN RECEPTOR ANTAGONIST; HERBACEOUS AGENT; HYDROXYUREA; NIPRISAN; NITRIC OXIDE; NIX 0699; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; BLOOD TRANSFUSION; CHRONIC DISEASE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; EYELID EDEMA; HEADACHE; HEALTH CARE SYSTEM; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALARIA; MORTALITY; MULTIPLE ORGAN FAILURE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SICKLE CELL ANEMIA; SMOOTH MUSCLE RELAXATION; THROMBOCYTE ACTIVATION;

AFRICA; ANEMIA, SICKLE CELL; HUMANS; HYPERTENSION, PULMONARY; RISK FACTORS; UNITED STATES;

EID: 38349033336     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21057     Document Type: Review

References (77)

1. Serjeant GR. The case for dedicated sickle cell centers. Ind J Hum Genet 2006;12:148-151.
2. http://www.who.int/genomics/public/Maphaemoglobin.pdf
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
4. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
5. Ataga KI, Sood N, De Gent G, et al. Pulmonary hypertension in sickle cell disease. Am J Med 2004;117:665-669.
6. Hagar RW, Morris CR, Vichinsky EP. Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function. Br J Haematol 2006;133:433-435.
7. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2007;137:181-192.
8. Aliyu ZY, Tumblin AR, Kato GJ. Current therapy of sickle cell disease. Haematologica 2006;91:7-10.
9. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-1030.
10. Stuart MJ, Setty BN. Sickle cell acute chest syndrome:pathogenesis and rationale for treatment. Blood 1999;94:1555-1560.
11. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA 2005;294:81-90.
12. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-1389. Epub 2002 Nov 11.
13. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005;293:1653-1662.
14. Verresen D, De Backer W, Van Meerbeeck J, et al. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J 1991;4:629-631.
15. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007;21:37-47. Epub 2006 Nov 7.
16. Nolan VG, Wyszynski DF, Fairer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood 2005;106:3264-3267. Epub 2005 Jun 28.
17. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006;133:570-578.
18. Sebastiani P, Nolan VG, Baldwin CT, et al. Severity of sickle cell disease: Modeling interrelationships among hemolysis, pulmonary hypertension and risk of death. American Society of Hematology Annual Meeting 2007.
19. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84:643-649.
20. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: Mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 2005;19:881-896, vii. Review.
21. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-523.
22. Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol 1990;66:493-496.
23. Sutton LL, Castro O, Cross DJ, et al. Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994;74:626-628.
24. Powars D, Weidman JA, Odom-Maryon T, et al. Sickle cell chronic lung disease: Prior morbidity and the risk of pulmonary failure. Medicine 1988;67:66-76.
25. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: A longitudinal study. Br J Haematol 2006;134:109-115.
26. De Castro LM, Jonassiant JC, Graham FL, et al. Pulmonary hypertension in SS, SC and S, thalassemia: Prevalence associated clinical syndromes, and mortality. Blood 2004;104:462a.
27. Nelson SC, Adade BB, McDonough EA, et al. High prevalence of pulmonary hypertension in children with sickle cell disease. J Pediatr Hematol Oncol 2007;29:334-337.
28. Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary hypertension in sickle cell disease: Relevance to children. Pediatr Hematol Oncol 2007;24:159-170.
29. Costello-Boerrigter LC, Burnett JC Jr. The prognostic value of N-terminal proB-type natriuretic peptide. Nat Clin Pract Cardiovasc Med 2005;2:194-201. Review.
30. Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 2006;296:310-318.
31. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003;101:1257-1261.
32. Machado RF, Kyle Mack A, Martyr S, et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol 2007;136:319-825. Epub 2006 Dec 8.
33. Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol 2007;49:472-479.
34. Sickle-cell anaemia Report by the Secretariat Fifty-Ninth World Health Assembly A59/9 Provisional agenda item 11.4 24 April 2006.
35. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: An increasing global health problem. Bull World Health Organ 2001;79.
36. Aliyu ZY, Kato GJ, Gladwin MT, Taylor JT. IV: Prevalence of pulmonary hypertension among African Immigrants with sickle cell disease in the United States. Abstract. Southern Medical Association, 101st Scientific Assembly, North Carolina, 2006.
37. Aliyu ZY. NIH/NHLBI Vascular Medicine Branch-Ahmadu Bello University Hospital, Zaria, Nigeria Sickle Cell Pulmonary Hypertension Screening Protocol, 2006.
38. UNAIDS. http://www.unaids.org/en/Regions_Countries/Countries Accessed 28 April 2007.
39. Barbosa MM, Lamounier JA, Oliveira EC, et al. Pulmonary hypertension in schistosomiasis mansoni. Trans R Soc Trop Med Hyg 1996;90:663-665.
40. de Cleva R, Herman P, Pugliese V, et al. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis - Prospective study. Hepatogastroenterology 2003;50:2028-2030.
41. Kcomt W, Nahavandi AA, Myaing M, et al. Hepatitis C and the heart: To beat or not to beat. Int J Cardiol. 2004;96:147-149.
42. Sarinas PS, Chitkara RK. Ascariasis and hookworm. Semin Respir Infect 1997;12:130-137.
43. Friese G, Lohmeyer J, Seeger W, et al. HIV-associated pulmonary hypertension. Herz 2005;30:481-485.
44. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133-1141.
45. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030. Epub 2006 Feb 2.
46. Onyekwere O. Severe pulmonary hypertension in sickle cell and HIV/AIDS. American Society of Hematology Scientific Meeting, San Diego, CA, 2003.
47. Odum CU, Anorlu RI, Dim SI, Oyekan TO. Pregnancy outcome in HbSS-sickle cell disease in Lagos, Nigeria. West Afr J Med 2002;21:19-23.
48. Makani J, Williams TN, Marsh K. Sickle cell disease in Africa: burden and research priorities. Ann Trop Med Parasitol 2007;101:3-14. Review.
49. Gramaglia I, Sobolewski P, Meays D, et al. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nat Med 2006;12:1417-1422. Epub 2006 Nov 12.
50. Huchzermeyer FW. Avian pulmonary hypertension syndrome. IV. Increased right ventricular mass in turkeys experimentally infected with Plasmodium durae. Onderstepoort J Vet Res 1988;55:107-108.
51. Wang J, Wang X, Xiang R, Sun W. Effect of L-NAME on pulmonary arterial pressure, plasma nitric oxide and pulmonary hypertension syndrome morbidity in broilers. Br Poult Sci 2002;43:615-620.
52. Hsu LL, Champion HC, Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2006. [Epub ahead of print].
53. Sen S, Biswas PK, Biswas J, et al. Primary pulmonary hypertension in cirrhosis of liver. Ind J Gastroenterol 1999;18:158-160.
54. Jombo GT, Egah DZ, Banwat EB. Hepatitis B virus infection in a rural settlement of northern Nigeria. Niger J Med 2005;14:425-428.
55. Nwokedi EE, Emokpae MA, Dutse AI. Human immunodeficiency virus and hepatitis B virus co-infection among patients in Kano Nigeria. Niger J Med 2006;15:227-229.
56. Lesi OA, Kehinde MO. Hepatitis C virus infection in patients with sickle cell anaemia at the Lagos University Hospital. Niger Postgrad Med J 2003;10:79-83.
57. Hassan M, Hasan S, Castro O, et al. HCV in sickle cell disease. J Natl Med Assoc 2003;95:864-867, 872-874. Review.
58. Hassan M, Hasan S, Giday S, et al. Hepatitis C virus in sickle cell disease. J Natl Med Assoc 2003;95:939-942.
59. Machado RF, Gladwin MT. Hemolytic anemia associated pulmonary hypertension. In: Mandel J, Taissman D, editors. Pulmonary Vascular Disease, 1st ed. Philadelphia, PA: Saunders Elsevier, 2006.
60. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651. Erratum in: JAMA 2003;290:756.
61. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine (Baltimore) 1996;75:300-326.
62. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000;342:1855-1865.
63. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003;111:231-239.
64. Wambebe C, Khamofu H, Momoh JA, et al. Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with sickle cell disorder. Phytomedicine 2001;8:252-261.
65. http://www.genengnews.com/news. Last accessed April 8th 2007.
66. Gordeuk VR. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005;90:433-434.
67. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005;130:445-453.
68. Gorkin L, Hvidsten K, Sobel RE, et al. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006;60:500-503.
69. Fraunfelder FW, Shults T. Non-arteritic anterior ischemic optic neuropathy, erectile dysfunction drugs, and amiodarone: Is there a relationship? J Neuroophthalmol 2006;26:1-3.
70. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69. Epub 2003 Mar 5.
71. Sullivan KJ, Goodwin SR, Evangelist J, et al. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med 1999;27:2563-2568.
72. Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2003;289:1136-1142; 2004;292:925.
73. Gladwin MT, Schechter AN. Nitric oxide therapy in sickle cell disease. Semin Hematol 2001;38:333-342. Review.
74. Raghavachari N, Xu X, Harris A, et al. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation 2007;115:1551-1562. Epub 2007 Mar 12.
75. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006;81:858-863.
76. http://www.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf. Accessed May 10th 2007.
77. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:10S. (Modification of World Health Organization Pulmonary Hypertension Classification).